Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1994-06-28
1999-03-02
Smith, Lynette F.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
4242081, 4242041, 4241841, 530324, 530395, 514 8, A61K 3921, A61K 3816, A61K 3800, C07K 100
Patent
active
058767240
ABSTRACT:
The invention comprises a method of enhancing the immunogenicity of an envelope virus glycoprotein in a host organism. The method comprises administering to the host a composition comprising the virus envelope glycoprotein and at least one oligopeptide derived from the amino acid sequence of the envelope glycoprotein, wherein the oligopeptide contains or corresponds to virus-neutralization epitopes. The method and compositions are useful for vaccinating against viruses, such as HIV, SIV, HTLV-I, HTLV-II, or any retrovirus capable of inducing AIDS in its natural host.
REFERENCES:
patent: 4956273 (1990-09-01), Kennedy et al.
patent: 5013548 (1991-05-01), Haynes et al.
Haynes, 1993, "Scientific and Social Issues . . . " Science 260: 1279-1286.
Robey et al., 1986, "Prospect for prevention of . . . " PNAS 83: 7023-7027.
Neurath et al., 1990, "Confronting the hyper variability of an . . . " Molecular Immunology 27(6):539-549.
Gordon R. Dreesman et al., "Antibody to hepatitis B surface antigen after a single inoculation of uncoupled synthetic HBsAG peptides," Nature, vol. 295, Jan. 14, 1982, pp. 158-160.
Kemp B. Cease et al., "Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein using a 16-residue synthetic peptide," Proc. Natl. Acad. Sci. USA, vol. 84, Jun. 1987, pp. 4249-4253.
Jap Goudsmit et al., "Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees," Proc. Natl. Acad. Sci. USA, vol. 85, Jun. 1988, pp. 4478-4482.
Robert Gallo et al., "HIV-HTLV gene nomenclature," Nature, vol. 333, Jun. 9, 1988, pp. 504-505.
Jay A. Berzofsky et al., "Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans," Nature, vol. 334, Aug. 25, 1988, pp. 706-708.
Kashi Javaherian et al., "Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein," Proc. Natl. Acad. Sci. USA 86, Sep. 1989, pp. 6768-6772.
Beatrice Culmann et al., "An antigenic peptide of the HIV-1 NEF protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-B molecules," Eur. J. Immunol., vol. 19, 1989, pp. 2383-2386.
Karl Deres et al., "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine," Nature, vol. 342, Nov. 30, 1989, pp. 561-564.
Girard et al., Proc. Natl. Acad. Sci. USA, 88, 542-546 (1991).
Rusche et al., Proc. Natl. Acad. Sci. USA, 85, 3,198-3,202 (1988).
Institut Pasteur
Smith Lynette F.
LandOfFree
Induction of neutralizing antibody against viral infection by sy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Induction of neutralizing antibody against viral infection by sy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Induction of neutralizing antibody against viral infection by sy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-419789